Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.54 |
| ▸ | HTR2B | P41595 | 1/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | PTK2B | Q14289 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | SGMS2 | Q8NHU3 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11360571 | 1.00 | LMNA (0.54) | LMNAKMT2AMAPTMEN1NR1I2 | |
| SCHEMBL8924404 | 0.95 | LMNA (0.58) | LMNAKMT2AMAPTMEN1NR1I2 | |
| SCHEMBL1045431 | 0.87 | LMNA (0.72) | LMNAKMT2AMAPTMEN1NR1I2 | |
| SCHEMBL9626775 | 0.87 | LMNA (0.72) | LMNAKMT2AMAPTMEN1NR1I2 | |
| SCHEMBL6112609 | 0.87 | LMNA (0.72) | LMNAKMT2AMAPTMEN1NR1I2 | |
| SCHEMBL1983637 | 0.87 | LMNA (0.72) | LMNAKMT2AMAPTMEN1NR1I2 | |
| SCHEMBL8982634 | 0.87 | LMNA (0.72) | LMNAKMT2AMAPTMEN1NR1I2 | |
| SCHEMBL8982612 | 0.87 | LMNA (0.72) | LMNAKMT2AMAPTMEN1NR1I2 | |
| SCHEMBL28554338 | 0.87 | LMNA (0.72) | LMNAKMT2AMAPTMEN1NR1I2 | |
| SCHEMBL10506979 | 0.87 | LMNA (0.72) | LMNAKMT2AMAPTMEN1NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1412447-B1 | NOVEL MESOGENS AND METHODS FOR THEIR SYNTHESIS AND USE | SOUTHWEST RES INST (US) | 2008-09-10 | — | — | EP | disclosed |
| EP-1572716-B1 | METHODS FOR SYNTHESIS OF LIQUID CRYSTALS | SOUTHWEST RES INST (US) | 2006-09-27 | — | — | EP | disclosed |
| US-7098359-B2 | Mesogens and methods for their synthesis and use | SOUTHWEST RESEARCH INSTITUTE (US) | 2006-08-29 | — | — | US | disclosed |
| US-7094360-B2 | Resin blends and methods for making same | SOUTHWEST RESEARCH INSTITUTE (US) | 2006-08-22 | — | — | US | disclosed |
| EP-1572716-A4 | METHODS FOR SYNTHESIS OF LIQUID CRYSTALS | SOUTHWEST RES INST (US) | 2005-09-14 | — | — | EP | disclosed |
| EP-1572716-A2 | METHODS FOR SYNTHESIS OF LIQUID CRYSTALS | Southwest Research Institute (US) | 2005-09-14 | — | — | EP | disclosed |
| US-20050189516-A1 | Resin blends and methods for making same | SOUTHWEST RESEARCH INSTITUTE (US) | 2005-09-01 | — | — | US | disclosed |
| US-20030168633-A1 | Novel, mesogens and methods for their synthesis and use | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-09-11 | — | — | US | disclosed |
| US-20030055280-A1 | Methods for synthesis of liquid crystals | SOUTHWEST RESEARCH INSTITUTE | 2003-03-20 | — | — | US | disclosed |
| US-20020177727-A1 | Novel mesogens | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-11-28 | — | — | US | disclosed |
| WO-2002066493-A2 | METHODS FOR SYNTHESIS OF LIQUID CRYSTALS | SOUTHWEST RESEARCH INSTITUTE (US) | 2002-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055280-A1 | Methods for synthesis of liquid crystals | WEE1, WEE2, NUP188 | LMNA 2338/4885KMT2A 4008/4885MAPT 1197/4885 |
| US-20020177727-A1 | Novel mesogens | AREG, MAG, GMFG | LMNA 3677/4885KMT2A 2256/4885MAPT 2590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.